New Immunotherapy Therapy Approved for Lymphoma Patients

The Food and Drug Administration (FDA) approved a new kind of immunotherapy drug for adults and children with classical Hodgkin lymphoma who have relapsed after three or more prior lines of therapy.

The approved drug, pembrolizumab (Keytruda), is part of a class of immunotherapy drugs called checkpoint inhibitors that block the PD-1 protein, which is commandeered by cells to avoid detection and attack by the body’s immune system. Since 2015, Keytruda has been approved in patients with advanced bladder cancer, melanoma, head and neck cancer, and lung cancer.

This wave of immunotherapy research, in which Dana-Farber scientists have played a prominent role, focuses on amassing the power of the body’s immune system to seek out and destroy cancer cells.

Margaret Shipp, MD, is also studying the benefits of pembrolizumab (Keytruda) or nivolumab (Opdivo) in patients with non-Hodgkin lymphoma.

“The compelling early data support the clinical evaluation of PD-1 blockade in specific additional lymphoma malignancies,” Shipp says.

Read more from the Leukemia and Lymphoma Society, and learn more about immunotherapy at Dana-Farber.

Comments Sort By Newest

Leave a Reply

Your email address will not be published. Required fields are marked *

Blue Captcha Image


Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Human Touch Surgeries, New Therapies Brighten the Picture in Endometrial Cancer:
Dana-Farber @danafarber
Join @BCRFcure on Facebook Live today as experts discuss advancements in metastatic breast cancer research:…
Dana-Farber @danafarber
Fact Check: Can Breast Implants Cause Cancer?

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at